Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
2.340
-0.020 (-0.85%)
At close: Aug 28, 2026, 4:00 PM EDT
2.335
-0.005 (-0.21%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Autolus Therapeutics Revenue
Autolus Therapeutics had revenue of $45.69M in the quarter ending June 30, 2026, with 118.37% growth. This brings the company's revenue in the last twelve months to $117.39M, up 293.55% year-over-year. In the year 2025, Autolus Therapeutics had annual revenue of $75.39M with 652.77% growth.
Revenue (ttm)
$117.39M
Revenue Growth
+293.55%
P/S Ratio
5.31
Revenue / Employee
$155,690
Employees
754
Market Cap
622.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75.39M | 65.37M | 652.77% |
| Dec 31, 2024 | 10.01M | 8.32M | 489.80% |
| Dec 31, 2023 | 1.70M | -4.68M | -73.38% |
| Dec 31, 2022 | 6.38M | 4.87M | 323.23% |
| Dec 31, 2021 | 1.51M | 1.27M | 522.73% |
| Dec 31, 2020 | 242.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Sep 30, 2018 | - | - | - |
| Sep 30, 2017 | - | - | - |
| Sep 30, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Arvinas | 316.70M |
| REGENXBIO | 174.48M |
| Valneva SE | 163.30M |
| OmniAb | 38.46M |
| Prime Medicine | 4.07M |
| Altimmune | 31.00K |
AUTL News
- 11 days ago - Autolus Therapeutics Slides: Corporate presentation - Filings
- 18 days ago - Autolus Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 18 days ago - Autolus Therapeutics Earnings release: Q2 2026 - Filings
- 18 days ago - Autolus Therapeutics Earnings release: Q2 2026 - Filings
- 18 days ago - Autolus Therapeutics Slides: Q2 2026 - Filings
- 18 days ago - Autolus Therapeutics Quarterly report: Q2 2026 - Filings
- 18 days ago - Autolus Therapeutics raises FY26 revenue view to $140M-$150M from $120M-$135M - TheFly
- 18 days ago - Autolus Therapeutics reports Q2 EPS (15c), consensus (19c) - TheFly